Drug Targeting Organ-Specific Strategies

304 11 Development of Proteinaceous Drug Targeting Constructs
11.10 Concluding Remarks
This chapter has presented many approaches to the preparation of drug targeting constructs.
In these constructs, a protein or part of it may function as a carrier for attached drug molecules,
as a specific targeting moiety, or as a therapeutically active substance. Two entirely different
approaches have been followed in the preparation of proteinaceous drug targeting
constructs. First, chemical derivatization of existing proteins with site-directing ligands
and/or drug molecules, and second, the engineering and expression of recombinant DNA
constructs. Depending on the type of construct required, each approach has its own unique
advantages. For instance, the engineering of protein backbone structures is most accurately
performed by recombinant techniques. On the other hand, chemical approaches can be used
for the attachment of small organic drug molecules, offering numerous opportunities for
therapeutic intervention which cannot be matched by proteinaceous drug substances. Therefore,
with reference to the title of this chapter, proteinaceous drug targeting constructs
should preferably be prepared by chemical and recombinant DNA techniques, rather than by
the exclusive use of either one.
Acknowledgements
R. J. Kok and S. A. Ásgeirsdóttir are members of UNYPHAR, a network collaboration between
the universities of Groningen, Leiden and Utrecht and the pharmaceutical company
Yamanouchi.
References
[1] Forssen E, Willis M, Adv. Drug Deliv. Rev 1998, 29, 249–271.
[2] Seymour LW, Adv. Drug Deliv. Rev. 1994, 14, 89–111.
[3] Brocchini S, Duncan R, In: Encyclopedia of Controlled Drug Delivery (Ed. Mathiowitz E), pp.
786–816. John Wiley and Sons, New York, 1999.
[4] Meijer DKF, Molema G, Moolenaar F, De Zeeuw D, Swart PJ, J. Control. Rel. 1996, 39, 163–172.
[5] Maack T, Johnson V, Kau ST, Figuereido J, Sigulem D, Kidney Int. 1979, 16, 251–270.
[6] Stehle G, Wunder A, Schrenk HH, Hartung G, Heene DL, Sinn H, Anti-Cancer Drugs 1999, 10,
785–790.
[7] Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, J. Control. Rel. 2000, 65, 271–284
[8] Stehle G, Sinn H, Wunder A, Schrenk HH, Schutt S, Maierborst W, Heene DL, Anti-Cancer
Drugs 1997, 8, 677–685.
[9] Franssen EJF, Jansen RW, Vaalburg M, Meijer DKF, Biochem. Pharmacol. 1993, 45, 1215–1226.
[10] Melgert BN, Wartna E, Lebbe C, Albrecht C, Molema G, Poelstra K, Reichen J, Meijer DKF, J.
Drug Target. 1998, 5, 329–342.
[11] Melgert BN, Olinga P, Jack VK, Molema G, Meijer DKF, Poelstra K, J. Hepatol. 2000, 32,
603–611.
[12] Haas M, Meijer DKF, Moolenaar F, De Jong PE, De Zeeuw D, In: International Yearbook of
Nephrology 1996 (Eds. Andreucci VE, Fine LG), pp. 3–11. Oxford University Press, Oxford, UK,
1996.
[13] Franssen EJF, Moolenaar F, De Zeeuw D, Meijer DKF, Adv. Drug Deliv. Rev. 1994, 14, 67–88.
[14] Kok RJ, Grijpstra F, Walthuis RB, Moolenaar F, De Zeeuw D, Meijer DKF, J. Pharmacol. Exp.
Ther. 1999, 288, 281–285.
[15] Haas M, Kluppel ACA, Wartna ES, Moolenaar F, Meijer DKF, De Jong PE, De Zeeuw D, Kidney
Int. 1997, 52, 1693–1699.